Universe Pharmaceuticals Financials
UPC Stock | USD 1.86 0.07 3.63% |
Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Debt Equity Ratio | 0.17 | 0.16 |
|
| |||||
Current Ratio | 2.22 | 2.41 |
|
|
The essential information of the day-to-day investment outlook for Universe Pharmaceuticals includes many different criteria found on its balance sheet. An individual investor should monitor Universe Pharmaceuticals' cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Universe Pharmaceuticals.
Net Income |
|
Universe | Select Account or Indicator |
Understanding current and past Universe Pharmaceuticals Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Universe Pharmaceuticals' financial statements are interrelated, with each one affecting the others. For example, an increase in Universe Pharmaceuticals' assets may result in an increase in income on the income statement.
Please note, the presentation of Universe Pharmaceuticals' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Universe Pharmaceuticals' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Universe Pharmaceuticals' management manipulating its earnings.
Universe Pharmaceuticals Stock Summary
Universe Pharmaceuticals competes with Regencell Bioscience, Im Cannabis, Raphael Pharmaceutical, Procaps Group, and Phibro Animal. Universe Pharmaceuticals INC, a pharmaceutical company, engages in the manufacture, marketing, distribution, and sale of traditional Chinese medicine derivative products in China. Universe Pharmaceuticals INC is a subsidiary of Sununion Holding Group Limited. Universe Pharmaceuticals is traded on NASDAQ Exchange in the United States.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
Instrument | USA Stock View All |
Exchange | NASDAQ Exchange |
ISIN | KYG9442G1047 |
CUSIP | G9442G104 G9442G112 |
Location | China |
Business Address | 265, Jingjiu Avenue, |
Sector | Biotechnology |
Industry | Health Care |
Benchmark | Dow Jones Industrial |
Website | www.universe-pharmacy.com |
Phone | 86 79 6840 3309 |
Currency | USD - US Dollar |
Universe Pharmaceuticals Key Financial Ratios
Return On Equity | -0.5 | ||||
Profit Margin | (0.69) % | ||||
Operating Margin | (0.14) % | ||||
Price To Sales | 0.11 X | ||||
Revenue | 32.31 M |
Universe Pharmaceuticals Key Balance Sheet Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 28.8M | 70.1M | 59.5M | 53.3M | 61.3M | 47.2M | |
Other Current Liab | 1.3M | 464.0K | 5.9M | 3.3M | 2.9M | 3.2M | |
Net Tangible Assets | 12.2M | 20.6M | 58.8M | 46.3M | 53.2M | 32.4M | |
Net Debt | (7.4M) | (3.7M) | (1.8M) | 197.2K | 226.8K | 238.1K | |
Retained Earnings | 13.7M | 25.1M | 16.3M | 10.2M | 11.7M | 13.6M | |
Accounts Payable | 2.7M | 5.3M | 3.1M | 4.6M | 5.3M | 3.8M | |
Cash | 10.1M | 8.1M | 5.7M | 5.3M | 6.1M | 7.1M | |
Other Assets | 168.1K | 186.5K | 14.1M | 12.9M | 14.9M | 15.6M | |
Net Receivables | 10.9M | 15.8M | 15.2M | 10.7M | 12.3M | 12.2M | |
Inventory | 1.9M | 2.5M | 2.2M | 3.3M | 3.0M | 2.8M | |
Other Current Assets | 443.7K | 10.4M | 5.3M | 4.2M | 4.9M | 3.7M | |
Total Liab | 8.0M | 11.2M | 13.1M | 13.8M | 15.8M | 12.8M | |
Net Invested Capital | 23.4M | 63.3M | 50.4M | 45.0M | 51.8M | 38.4M | |
Short Long Term Debt | 2.6M | 4.3M | 3.9M | 5.5M | 6.3M | 3.9M | |
Total Current Assets | 23.3M | 50.5M | 41.5M | 36.8M | 42.3M | 34.1M | |
Net Working Capital | 15.3M | 39.3M | 28.4M | 23.1M | 26.5M | 21.3M | |
Short Term Debt | 2.6M | 4.3M | 3.9M | 5.5M | 6.3M | 3.9M | |
Intangible Assets | 174.8K | 178.5K | 157.5K | 148.6K | 133.7K | 135.3K |
Universe Pharmaceuticals Key Income Statement Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Tax Provision | 2.5M | 2.4M | 752.4K | 2.3M | 2.1M | 1.6M | |
Net Interest Income | (123.8K) | (101.6K) | (162.4K) | (156.8K) | (141.1K) | (148.2K) | |
Interest Expense | 123.8K | 101.6K | 162.4K | 156.8K | 180.3K | 153.8K | |
Total Revenue | 30.7M | 48.0M | 40.1M | 32.3M | 37.2M | 39.0M | |
Gross Profit | 14.1M | 25.3M | 21.9M | 10.1M | 11.6M | 18.0M | |
Operating Income | 10.3M | 13.6M | (7.0M) | (3.5M) | (3.2M) | (3.0M) | |
Ebit | 10.2M | 13.7M | (7.9M) | (3.7M) | (3.4M) | (3.2M) | |
Research Development | 583.1K | 5.5M | 7.6M | 4.9M | 5.6M | 3.7M | |
Ebitda | 10.6M | 14.2M | (7.3M) | (3.2M) | (2.9M) | (2.7M) | |
Cost Of Revenue | 16.6M | 22.7M | 18.3M | 22.2M | 25.6M | 21.0M | |
Income Before Tax | 10.1M | 13.7M | (8.0M) | (3.8M) | (3.5M) | (3.3M) | |
Net Income | 7.6M | 11.3M | (8.7M) | (6.2M) | (5.5M) | (5.3M) | |
Income Tax Expense | 2.5M | 2.4M | 752.4K | 2.3M | 2.1M | 1.6M |
Universe Pharmaceuticals Key Cash Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Change To Inventory | 888.6K | (451.6K) | 16.6K | (1.2M) | (1.1M) | (1.0M) | |
Investments | (51.8K) | (13.5M) | (3.9M) | (44.2K) | (39.8K) | (41.7K) | |
Change In Cash | 6.9M | (2.0M) | (2.4M) | (426.2K) | (383.6K) | (402.8K) | |
Net Borrowings | 1.1K | 911.2K | 624.4K | 3.3M | 3.8M | 4.0M | |
Free Cash Flow | 6.1M | (15.6M) | (1.4M) | 1.1M | 968.3K | 1.0M | |
Depreciation | 410.1K | 446.9K | 533.9K | 508.8K | 585.1K | 508.0K | |
Other Non Cash Items | 22.7K | (468.2K) | 906.6K | (526.9K) | (474.2K) | (450.5K) | |
Capital Expenditures | 51.8K | 13.5M | 93.7K | 44.2K | 50.8K | 48.3K | |
Net Income | 7.6M | 11.3M | (8.7M) | (6.2M) | (5.5M) | (5.3M) | |
End Period Cash Flow | 10.1M | 8.1M | 5.7M | 5.3M | 6.1M | 7.1M | |
Change To Netincome | 73.2K | 12.8K | (1.1M) | 301.3K | 271.2K | 284.7K |
Universe Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Universe Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Universe Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Universe Pharmaceuticals competition to find correlations between indicators driving Universe Pharmaceuticals's intrinsic value. More Info.Universe Pharmaceuticals is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . At present, Universe Pharmaceuticals' Return On Equity is projected to slightly decrease based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Universe Pharmaceuticals' earnings, one of the primary drivers of an investment's value.Universe Pharmaceuticals Systematic Risk
Universe Pharmaceuticals' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Universe Pharmaceuticals volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twelve with a total number of output elements of fourty-nine. The Beta measures systematic risk based on how returns on Universe Pharmaceuticals correlated with the market. If Beta is less than 0 Universe Pharmaceuticals generally moves in the opposite direction as compared to the market. If Universe Pharmaceuticals Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Universe Pharmaceuticals is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Universe Pharmaceuticals is generally in the same direction as the market. If Beta > 1 Universe Pharmaceuticals moves generally in the same direction as, but more than the movement of the benchmark.
About Universe Pharmaceuticals Financials
What exactly are Universe Pharmaceuticals Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include Universe Pharmaceuticals' income statement, its balance sheet, and the statement of cash flows. Potential Universe Pharmaceuticals investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Universe Pharmaceuticals investors may use each financial statement separately, they are all related. The changes in Universe Pharmaceuticals's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Universe Pharmaceuticals's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.Today, most investors in Universe Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Universe Pharmaceuticals' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Universe Pharmaceuticals growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Universe Pharmaceuticals November 25, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Universe Pharmaceuticals help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Universe Pharmaceuticals. We use our internally-developed statistical techniques to arrive at the intrinsic value of Universe Pharmaceuticals based on widely used predictive technical indicators. In general, we focus on analyzing Universe Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Universe Pharmaceuticals's daily price indicators and compare them against related drivers.
Information Ratio | (0.30) | |||
Maximum Drawdown | 73.25 | |||
Value At Risk | (16.26) | |||
Potential Upside | 12.27 |
Complementary Tools for Universe Stock analysis
When running Universe Pharmaceuticals' price analysis, check to measure Universe Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Universe Pharmaceuticals is operating at the current time. Most of Universe Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Universe Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Universe Pharmaceuticals' price. Additionally, you may evaluate how the addition of Universe Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Global Correlations Find global opportunities by holding instruments from different markets | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk |